Saturday, 17 June 2017

Recent Research into the Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. 
The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Respiratory, Immunology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Other Diseases which include indications Breast Cancer, Asthma, Autoimmune Disorders, Chronic Inflammation, Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Acute Inflammation, Atherosclerosis, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Obstructive Pulmonary Disease (COPD), Colitis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Foot Ulcers, Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Peritoneal Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Venous Leg Ulcers (Crural ulcer), West Nile Virus Infections, Wounds and Zika Virus Infections.
Furthermore, this report also reviewsalso reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
- The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Hemispherx Biopharma Inc Innate Pharma SA Johnson & Johnson MultiCell Technologies Inc Oncovir Inc RMB-Research GmbH
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home